Oxford, UK – 28 July 2015. OGT, The Molecular Genetics Company, is extending its portfolio of CytoCell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH.
The new additions to the CytoCell range include high-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13, ROS1-GOPC and RET. In addition to pathology probes, a large number of other probes are available, including haematology and haematopathology probes, as well as whole chromosome and murine chromosome painting probes. Importantly, CytoCell FISH probes provide bright signals for accurate scoring leading to consistent results, backed up by full evaluation support from OGT. Dr Eric Crawford, senior director, Genetics Associates Inc., discusses his experience of OGT’s CytoCell FISH products: "Not only do CytoCell offer an extensive range of high-quality FISH probes, the customer support is also excellent — providing fast access to all the probes I need. The probes are highly consistent with bright signals allowing easy scoring of results."
The addition of eight new pathology probes highlights OGT’s ongoing commitment to the FISH market following its acquisition of CytoCell in June 2014. Dr Mike Evans, CEO of OGT commented: “We are delighted to be expanding our already extensive portfolio of CytoCell FISH probes. Through our exceptional probe quality and range, plus our dedicated support team, we believe that we offer the best value FISH products available.”
The new additions to the CytoCell Aquarius® Pathology range are currently only available within North America as Analyte Specific Reagents (ASRs). The products are available for sale from July 2015. CE-marked versions for sale in Europe are anticipated to launch later this year.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.Read
State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.Read